Innovent Mazdutide DREAMS-3 Head-to-Head Beats Semaglutide in Chinese Type 2 Diabetes: 48% Hit A1C Under 7% Plus 10% Weight Loss Versus 21% on Semaglutide
Innovent's DREAMS-3 Phase 3b head-to-head trial of mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity was presented Sunday June 7 by Linong Ji of Peking University People's Hospital. On the composite primary endpoint, 48.0% of mazdutide-treated patients reached HbA1c under 7% plus at least 10% body weight reduction versus 21.0% on semaglutide. The readout is the first Phase 3 head-to-head defeat for semaglutide outside Lilly's tirzepatide series.